Paid Clinical Trials Cleveland
Discover 1,515 paid clinical trials in Cleveland, Ohio. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease
Sponsor:
Pfizer
Location:
Code:
NCT04173273
Conditions
Crohn's Disease
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Etrasimod
Placebo
Endovascular Therapy for Low NIHSS Ischemic Strokes
Sponsor:
Emory University
Location:
Code:
NCT04167527
Conditions
Cerebral Ischemia
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Immediate mechanical thrombectomy(iMT) using EmboTrap Revascularization Device
Initial medical management (iMM)
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
Sponsor:
AbbVie
Location:
Code:
NCT05814627
Conditions
Rheumatoid Arthritis
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Upadacitinib
Adalimumab
Upadacitinib Matching Placebo
Adalimumab Matching Placebo
A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)
Sponsor:
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Location:
Code:
NCT04471727
Conditions
Small-Cell Lung Cancer
Neuroendocrine Carcinoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
MK-6070
Atezolizumab
Ifinatamab Deruxtecan (I-DXd)
A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder
Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.
Location:
Code:
NCT05729373
Conditions
Generalized Anxiety Disorder
Eligibility Criteria
Sex: All
Age: 18 - 65
Healthy Volunteers: Not accepted
Interventions
SEP-363856
Placebo
A Trial to Learn if Dupilumab is Safe for and Helps Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis
Sponsor:
Regeneron Pharmaceuticals
Location:
Code:
NCT05831176
Conditions
Eosinophilic Gastritis
Eosinophilic Duodenitis
Eosinophilic Gastrointestinal Disease
Eligibility Criteria
Sex: All
Age: 12+
Healthy Volunteers: Not accepted
Interventions
Dupilumab Dose 1
Dupilumab Dose 2
Matching Placebo
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT04181060
Conditions
Advanced Lung Non-Squamous Non-Small Cell Carcinoma
Metastatic Lung Non-Squamous Non-Small Cell Carcinoma
Recurrent Lung Non-Squamous Non-Small Cell Carcinoma
Stage IIIB Lung Cancer AJCC v8
Stage IV Lung Cancer AJCC v8
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Bevacizumab
Biospecimen Collection
Computed Tomography
Echocardiography
Magnetic Resonance Imaging
Human/Machine Interface: What the HeartMate 3 ® Device Tells Us About the Future
Sponsor:
International Consortium of Circulatory Assist Clinicians
Location:
Code:
NCT06039176
Conditions
LVAD
Frailty
GI Bleed
Right Heart Failure
Infections
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
HeartMate 3 (R) left ventricular assist device
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
Sponsor:
Alzheimer's Disease Cooperative Study (ADCS)
Location:
Code:
NCT06223360
Conditions
Alzheimer Disease
Eligibility Criteria
Sex: All
Age: 50 - 70+
Healthy Volunteers: Not accepted
Interventions
Low Dose Benfotiamine
High Dose Benfotiamine
Placebo